In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%.
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine